I. Beletskaya

发表

New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis

M. Cascio, D. Baker, V. Di Marzo, 2006, British journal of pharmacology.

Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics for affinity and function.

D. Selley, I. Beletskaya, Yunyun Yuan, 2013, Bioorganic & medicinal chemistry letters.

Discovery of Pyrazolo[1,5-a]pyrimidine TTK Inhibitors: CFI-402257 is a Potent, Selective, Bioavailable Anticancer Agent.

Narendra Kumar Patel, Y. Liu, T. Mak, 2016, ACS medicinal chemistry letters.

The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.

Narendra Kumar Patel, Y. Liu, T. Mak, 2015, Journal of medicinal chemistry.

Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.

Narendra Kumar Patel, T. Mak, N. Chirgadze, 2014, Bioorganic & medicinal chemistry.

Opioid receptor selectivity profile change via isosterism for 14-O-substituted naltrexone derivatives.

D. Selley, I. Beletskaya, Yunyun Yuan, 2013, Bioorganic & medicinal chemistry letters.

Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.

D. Selley, I. Beletskaya, Yunyun Yuan, 2011, Bioorganic & medicinal chemistry letters.

The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents.

Y. Liu, T. Mak, P. Sampson, 2013, Journal of medicinal chemistry.

The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.

Narendra Kumar Patel, Y. Liu, T. Mak, 2015, Journal of medicinal chemistry.

The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors.

C. Breivogel, M. Aceto, B. Martin, 2003, European journal of pharmacology.

Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.

D. Selley, I. Beletskaya, W. Dewey, 2012, Journal of medicinal chemistry.

Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.

Y. Liu, T. Mak, O. Plotnikova, 2016, Bioorganic & medicinal chemistry letters.

Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2

E. Pai, N. Chirgadze, R. Rottapel, 2014, Acta crystallographica. Section D, Biological crystallography.

Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer

T. Mak, I. Beletskaya, M. Bray, 2017, Proceedings of the National Academy of Sciences.

Design and optimization of (3-aryl-1H-indazol-6-yl)spiro[cyclopropane-1,3'-indolin]-2'-ones as potent PLK4 inhibitors with oral antitumor efficacy.

Narendra Kumar Patel, T. Mak, P. Sampson, 2016, Bioorganic & medicinal chemistry letters.

Participation of a GABA-ergic system in the processes of neuroimmunomodulation.

I. Beletskaya, L. Devoino, G. Idova, 1992, The International journal of neuroscience.

The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.

Narendra Kumar Patel, Y. Liu, T. Mak, 2015, Journal of medicinal chemistry.